Insider Transactions in Q1 2021 at Nabriva Therapeutics PLC (NBRV)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
107
-0.06%
|
$107
$1.66 P/Share
|
|
Mar 31
2021
|
Robert Crotty Gen Counsel & Corp Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
37
-0.09%
|
$37
$1.66 P/Share
|
|
Mar 31
2021
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
63
-0.08%
|
$63
$1.66 P/Share
|
|
Mar 06
2021
|
Robert Crotty Gen Counsel & Corp Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
71
-0.17%
|
$71
$1.79 P/Share
|
|
Mar 06
2021
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
92
-0.12%
|
$92
$1.79 P/Share
|
|
Mar 06
2021
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
225
-0.13%
|
$225
$1.79 P/Share
|
|
Feb 28
2021
|
Robert Crotty Gen Counsel & Corp Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
38
-0.09%
|
$76
$2.39 P/Share
|
|
Feb 28
2021
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
63
-0.08%
|
$126
$2.39 P/Share
|
|
Feb 28
2021
|
Jennifer Schranz Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
33
-0.08%
|
$66
$2.39 P/Share
|
|
Feb 28
2021
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
106
-0.06%
|
$212
$2.39 P/Share
|
|
Feb 28
2021
|
Gary Sender Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
31
-0.15%
|
$62
$2.39 P/Share
|
|
Feb 06
2021
|
Robert Crotty Gen Counsel & Corp Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
870
-2.04%
|
$1,740
$2.9 P/Share
|
|
Feb 06
2021
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,104
-1.41%
|
$2,208
$2.9 P/Share
|
|
Feb 06
2021
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,695
-1.48%
|
$5,390
$2.9 P/Share
|
|
Jan 31
2021
|
Gary Sender Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37
-0.18%
|
$74
$2.62 P/Share
|
|
Jan 31
2021
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
75
-0.1%
|
$150
$2.62 P/Share
|
|
Jan 31
2021
|
Jennifer Schranz Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
36
-0.09%
|
$72
$2.62 P/Share
|
|
Jan 31
2021
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
125
-0.07%
|
$250
$2.62 P/Share
|
|
Jan 31
2021
|
Robert Crotty Gen Counsel & Corp Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
43
-0.1%
|
$86
$2.62 P/Share
|
|
Jan 29
2021
|
Steven P. Gelone Director |
BUY
Grant, award, or other acquisition
|
Direct |
42,500
+35.2%
|
-
|
|
Jan 29
2021
|
Jennifer Schranz Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+36.47%
|
-
|
|
Jan 29
2021
|
Theodore R Schroeder Director |
BUY
Grant, award, or other acquisition
|
Direct |
117,500
+39.23%
|
-
|
|
Jan 29
2021
|
Robert Crotty Gen Counsel & Corp Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+34.45%
|
-
|